Morimoto, Kenji
Yamada, Tadaaki http://orcid.org/0000-0002-6945-281X
Takeda, Takayuki
Shiotsu, Shinsuke
Date, Koji
Tamiya, Nobuyo
Goto, Yasuhiro
Kanda, Hibiki
Chihara, Yusuke
Kunimatsu, Yusuke
Katayama, Yuki
Iwasaku, Masahiro
Tokuda, Shinsaku
Takayama, Koichi
Clinical trials referenced in this document:
Documents that mention this clinical trial
Clinical Efficacy and Safety of First- or Second-Generation EGFR-TKIs after Osimertinib Resistance for EGFR Mutated Lung Cancer: A Prospective Exploratory Study
https://doi.org/10.1007/s11523-023-00991-5
Article History
Accepted: 10 August 2023
First Online: 23 August 2023
Declarations
:
: No external funding was used in the preparation of this manuscript.
: Tadaaki Yamada received grants from Pfizer, Ono Pharmaceutical, Janssen Pharmaceutical, AstraZeneca, and Takeda Pharmaceutical as well as personal fees from Eli Lilly. Koichi Takayama received grants from Chugai Pharmaceutical and Ono Pharmaceutical as well as personal fees from AstraZeneca, Chugai Pharmaceutical, MSD, Eli Lilly, Boehringer Ingelheim, and Daiichi Sankyo. Kenji Morimoto, Takayuki Takeda, Shinsuke Shiotsu, Koji Date, Nobuyo Tamiya, Yasuhiro Goto, Hibiki Kanda, Yusuke Chihara, Yusuke Kunimatsu, Yuki Katayama, Masahiro Iwasaku, and Shinsaku Tokuda declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.
: The datasets generated during the current study are not publicly available because of ethical constraints. However, they are available from the corresponding author upon reasonable request.
: This study was approved by the Institutional Review Board of Kyoto Prefectural University of Medicine (ERB-C- 1731) and each participating hospital, registered at the University Medical Hospital Information Network (UMIN) Clinical Trials Registry (UMIN000044049), and performed in accordance with the Declaration of Helsinki.
: All patients provided written informed consent prior to participation in this prospective study. In addition, opt-out informed consent was provided at each hospital where the trial was conducted.
: Not applicable.
: TY was responsible for conceptualization, methodology, formal analysis, writing-original draft preparation, writing-review and editing, and supervision, KM for methodology, investigation, formal analysis, writing-original draft preparation, writing-review and editing, project administration, and data curation; TT for methodology; Shinsuke Shiotsu for investigation; Koji Date for investigation; Nobuyo Tamiya for investigation; YG for investigation; Hibiki Kanda for investigation; YC for investigation; YK for investigation; YK for project administration and data curation; MI for project administration and data curation; ST for project administration and data curation; and KT for writing-original draft preparation, writing-review and editing, and supervision.